Krystexxa™ (Pegloticase)

by | Sep 14, 2010 | Emerging Technology Report

An intravenous recombinant PEGylated formulation of porcine uricase for the treatment of chronic gout in patients with refractory disease or unable to tolerate current care therapy.If you have a Hayes login, click here to view the full report on the Knowledge...